Quick Facts

• Primary Use: Management of chronic Hepatitis C Virus (HCV) infection.
• Key Action: Used as a component of a combination antiviral treatment regimen.
• Patient Groups: Indicated for use in adults and children (typically aged 3 years and older) who meet specific requirements.

---

Sofovir (which contains the active ingredient sofosbuvir) is a medication used to manage chronic Hepatitis C Virus (HCV) infection. HCV is a viral infection that primarily affects the liver, causing inflammation and potential damage over time. This medication is indicated for use in combination with other approved antiviral agents, as it is not used as a stand-alone treatment.

Sofosbuvir-based regimens are part of the standard therapeutic approach for the treatment of various HCV genotypes in adults, and for specific groups of children who are at least 3 years old. The medication's role is to assist in reducing the viral load of the Hepatitis C virus in the body, which supports the clinical management of the chronic infection. In certain circumstances, the regimen may also be indicated for use in patients with HCV/HIV-1 coinfection or in those with hepatocellular carcinoma who are awaiting a liver transplant.

Sofosbuvir is used for the treatment of chronic hepatitis C virus infection in adults and children who meet specific requirements, as determined by a health care provider. The medication is indicated for use in specific patient populations based on established clinical criteria.

Regulatory References

1. EMA therapeutic overview

Sofovir (sofosbuvir) is a prescription medicine whose use is strictly defined by regulatory eligibility criteria. It is approved for use in adults and pediatric patients 3 years of age and older who have chronic Hepatitis C infection, and must always be administered as a component of a combination antiviral regimen. The medicine is also indicated for use in specific populations, including patients with HCV/HIV-1 co-infection and those with hepatocellular carcinoma awaiting liver transplantation. Use is generally permitted across all classes of hepatic impairment (Child-Pugh A, B, or C).

Sofovir is contraindicated in patients with known hypersensitivity to the active ingredient or any excipients. Use is conditionally contraindicated in pregnancy when the prescribed regimen includes Ribavirin due to the associated component risks. The medicine is not recommended for patients with severe renal impairment or End Stage Renal Disease (ESRD) requiring haemodialysis, as safety and appropriate dosage have not been established in this population. Similarly, use has not been established for children under 3 years of age or patients with decompensated cirrhosis. Co-administration with other sofosbuvir-containing products or certain potent P-gp inducers is also not recommended.

The official interaction profile for Sofovir (sofosbuvir) is defined by pharmacokinetic interactions involving drug transporters and a specific, serious pharmacodynamic risk.

Transporter-Mediated (PK) Interactions

Sofosbuvir is a substrate of the P-glycoprotein (P-gp) drug efflux transporter. The co-administration of potent P-gp inducers is not recommended because this interaction can significantly decrease the Sofosbuvir plasma concentration. Medicines and substances that act as potent P-gp inducers include Rifampin, Carbamazepine, Phenytoin, and the herbal product St. John’s wort. Reduced exposure carries a risk of reduced therapeutic effect. Conversely, P-gp inhibitors may increase Sofosbuvir exposure.

Pharmacodynamic (PD) Interaction and Restrictions

Co-administration of Amiodarone with a Sofovir combination regimen is not recommended due to the officially documented risk of serious symptomatic bradycardia and heart block. If this combination is medically necessary due to lack of alternatives, regulatory guidance requires in-patient cardiac monitoring for the initial 48 hours. This cardiovascular risk is heightened in patients with underlying cardiac comorbidities or advanced liver disease. Furthermore, the use of other medicinal products that contain sofosbuvir is not recommended to prevent unnecessary increased exposure. If activated charcoal is co-administered, the administration of Sofovir must be separated by four hours.

Viral Replication Enzyme Inhibition

Sofovir functions through two key mechanistic domains: viral enzyme inhibition and dependence on host cell metabolic activation. The molecule is an inactive prodrug that must first undergo essential metabolic conversion inside liver cells by specific host enzymes (kinases) to yield its active triphosphate form.

This active form directly targets the Hepatitis C Virus (HCV) NS5B polymerase, which is the enzyme essential for viral RNA replication. The metabolite acts as a competitive substrate that is incorporated into the nascent viral RNA strand. Its incorporation immediately causes chain termination, halting the enzyme's ability to synthesize a complete viral genome.

This molecular blockage leads to the physiological consequence of an arrest of new viral particle production within infected hepatocytes. The localized conversion results in a systemic decrease in the number of circulating viral RNA copies, which reduces the ongoing propagation of the virus.

Sofovir, which contains the active ingredient sofosbuvir, is administered via the oral route as a film-coated tablet. Its use is as a component of a combination antiviral regimen; the medicine is not used as a standalone therapy.

Standard Dosage and Administration

The standard adult dosing is 400 mg of sofosbuvir, taken once daily. This is a fixed dose, and dose reduction is generally not recommended. For children aged 3 years and older, the daily dose is weight-based, using either tablets or oral pellets.

Administration instructions regarding food may vary: the tablet may be taken with or without food, though some guidelines specify taking the dose with food. Regardless of meal timing, the tablet must be swallowed whole to avoid a bitter taste, and it should not be crushed or chewed.

Use Protocol and Duration

The total duration of the treatment course is fixed, typically lasting 12 or 24 weeks, based on the specific co-administered agents and the patient's clinical characteristics. The protocol addresses missed doses to maintain the schedule's integrity: if a dose is missed and it is within 18 hours of the scheduled time, it should be taken immediately. If more than 18 hours have passed, the missed dose is to be skipped, and the patient resumes the schedule at the next usual time, without taking a double dose.

Sofovir: Recent Clinical Evidence

---

Evidence for Use in Patients without Advanced Liver Disease

The research relies on large Randomized Controlled Trials (RCTs) examining Sofovir combination regimens in adults and children (typically ge 3 years) who were either treatment-naïve or treatment-experienced. The core measurement monitored is the Sustained Virologic Response (SVR), a viral clearance finding 12 weeks post-treatment ( SVR12). Research reports SVR measurements across all HCV types. While SVR12 patterns are clear, the relationship between SVR and long-term outcomes, such as overall survival, remains an area where data are still emerging through ongoing observational studies.

---

Evidence in Patients with Advanced Liver Conditions

For patients with compensated cirrhosis, dedicated Phase 3 RCTs and real-world analyses explored SVR12 and tracked how liver health markers changed. What remains uncertain is the full extent of the relationship between achieving SVR and reversing liver damage or reducing the long-term risk of conditions like liver cancer. For patients with severe decompensated cirrhosis, the evidence is based on smaller, targeted RCTs due to the health status of this group. These trials monitored SVR12 alongside clinical measures like MELD and Child-Pugh scores. However, findings were observed to be dependent on the exact regimen, and long-term effects are not fully established due to modest sample sizes.

---

Evidence in Specialized Patient Populations and Research Gaps

Research explored specific subgroups, including dedicated pediatric studies for children age 3 and older and cohort studies for patients with HCV/HIV-1 Co-infection and Kidney Impairment. These studies described virologic patterns and monitored outcomes like physical growth (in children). The evidence for these specialized groups is often based on smaller trials, meaning that subgroup findings are uncertain. Comparative evidence is lacking in the form of head-to-head RCTs against every single Direct-acting Antiviral combination available. Data are still emerging to characterize outcomes many years after SVR is achieved.

Key Studies & References

1. Hepatitis C Virus (HCV) Guidance: Recommendations for Testing, Managing, and Treating HCV – Patients With Decompensated Cirrhosis (AASLD/IDSA Guidelines)

Common questions about Sofovir (FAQ)

Q: What is Sofovir used for?

Sofovir (sofosbuvir) is a medication used to treat chronic hepatitis C virus (HCV) infection in adults. It is part of a class of medicines called nucleotide analog polymerase inhibitors. Sofovir is typically used in combination with other antiviral medications to cure the infection.

---

Q: How does Sofovir work?

Sofovir works by directly targeting and blocking the RNA polymerase enzyme (NS5B) that the hepatitis C virus uses to replicate its genetic material. By inhibiting this key enzyme, Sofovir prevents the virus from making new copies of itself, reducing the viral load and allowing the body to clear the infection when used with other antiviral drugs.

---

Q: What are the common side effects of Sofovir?

The most common side effects when Sofovir is used in combination with other medications may include headache, fatigue (tiredness), and nausea.

Side effects can vary depending on the other drugs it is combined with. Patients should consult their healthcare provider for a complete list of possible side effects for their specific treatment regimen.

---

Q: Who should not take Sofovir?

Patients should not take Sofovir if they have a known severe allergic reaction or hypersensitivity to the active ingredient, sofosbuvir, or any other components of the tablet.

Additionally, Sofovir (when used in combination with other drugs like ledipasvir, daclatasvir, or simeprevir) is not recommended with the heart rhythm medication amiodarone due to the risk of an abnormally slow heartbeat (severe bradycardia).

---

Q: Is it necessary to be tested for Hepatitis B before starting Sofovir treatment?

Yes, healthcare professionals generally recommend screening all individuals for hepatitis B virus (HBV) infection before starting treatment with Sofovir. In some patients with a history of HBV infection, taking direct-acting antiviral medications like Sofovir may cause the Hepatitis B virus to reactivate, which can lead to serious liver problems. Monitoring for HBV reactivation during and after treatment may be required.

---

Q: Can Sofovir be taken with other medications?

Sofovir has the potential to interact with several other medications, which could change how Sofovir or the other medication works. Of particular importance are medications that strongly influence an intestinal transporter protein called P-glycoprotein.

Examples of drugs that may reduce the effectiveness of Sofovir include rifampicin (an antibiotic) and the herbal supplement St. John’s wort. It is essential to inform your doctor or pharmacist about all medications, supplements, and herbal products you are taking.

The official regulatory documents specify mandatory requirements for the storage, protection, and disposal of Sofovir (sofosbuvir) to maintain product stability and safety.

Mandatory Storage Conditions

Requirement	Official Regulatory Wording
Temperature	Store below 30 C (86 F). Do not store above 30 C.
Packaging	Store only in the original container/bottle and keep it tightly closed.
Child Protection	Must be stored out of the reach and sight of children. The container has a child-resistant closure.

Disposal Instructions

Expired or unused Sofovir must be disposed of properly according to government guidelines. The product labeling directs users to follow established national drug disposal guidelines (such as FDA or DEA-authorized take-back programs). This means the product should not be placed in household trash or poured down a sink or toilet, except in the specific case of the household trash method after mixing with undesirable substances, if a take-back option is unavailable, and the drug is not on a mandatory flush list.